Key facts
- Glycomine’s last known valuation is $220.0M (Apr 2025).
- It has raised $195.6M across 1 recorded rounds; the latest was Seed Round ($4.9M) in Oct 2016.
- Notable investors include Novo Holdings, Johnson & Johnson Innovation - JLABS, Mission BioCapital, Sanderling Ventures, Aberdeen Investments (Scotland) — 21 tracked in total.
- Glycomine has filed 1 Form D with the SEC, most recently Nov 2016 ($4.9M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Glycomine
Funding rounds
1 roundsAbout Glycomine
Developer of orphan drugs designed to treat rare disorders of metabolism and protein misfolding. The company's drugs combine replacement therapies such as substrates, enzymes, and proteins with intracellular delivery vehicles consisting of bio-nano materials and ligands that target the molecules to the cell interior of clinically relevant organs, enabling physicians to efficiently treat their patients.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2015
- Employees
- 20
- Website
- glycomine.com/
- Ownership
- Privately Held (backing)
Glycomine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Glycomine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Glycomine in its N-PORT filings yet. We sweep new filings monthly.